title: Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.
abstract: The goal of an effective AIDS vaccine is to generate immunity that will prevent human immunodeficiency virus 1 (HIV-1) acquisition. Despite limited progress toward this goal, renewed optimism has followed the recent success of the RV144 vaccine trial in Thailand. However, the lack of complete protection in this trial suggests that breakthroughs, where infection occurs despite adequate vaccination, will be a reality for many vaccine candidates. We previously reported that neutralizing antibodies elicited by DNA prime-recombinant adenovirus serotype 5 (rAd5) boost vaccination with simian immunodeficiency virus strain mac239 (SIVmac239) Gag-Pol and Env provided protection against pathogenic SIVsmE660 acquisition after repeated mucosal challenge. Here, we report that SIV-specific CD8(+) T cells elicited by that vaccine lowered both peak and set-point viral loads in macaques that became infected despite vaccination. These SIV-specific CD8(+) T cells showed strong virus-inhibitory activity (VIA) and displayed an effector memory (EM) phenotype. VIA correlated with high levels of CD107a mobilization and perforin expression in SIV-specific CD8(+) T cells. Remarkably, both the frequency and the number of Gag CM9-specific public clonotypes were strongly correlated with VIA mediated by EM CD8(+) T cells. The ability to elicit such virus-specific EM CD8(+) T cells might contribute substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection.
authors.affiliation: Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
authors.forename: Takuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Johnson
authors.forename: David A
authors.initials: DA
authors.lastname: Price
authors.forename: David I
authors.initials: DI
authors.lastname: Wolinsky
authors.forename: Jorge R
authors.initials: JR
authors.lastname: Almeida
authors.forename: Constantinos
authors.initials: C
authors.lastname: Petrovas
authors.forename: Martha
authors.initials: M
authors.lastname: Nason
authors.forename: Wendy W
authors.initials: WW
authors.lastname: Yeh
authors.forename: Ling
authors.initials: L
authors.lastname: Shen
authors.forename: Mario
authors.initials: M
authors.lastname: Roederer
authors.forename: Srinivas S
authors.initials: SS
authors.lastname: Rao
authors.forename: Adrian B
authors.initials: AB
authors.lastname: McDermott
authors.forename: Francois
authors.initials: F
authors.lastname: Lefebvre
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: Elias K
authors.initials: EK
authors.lastname: Haddad
authors.forename: Norman L
authors.initials: NL
authors.lastname: Letvin
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Douek
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D015536:Down-Regulation; D015658:HIV Infections / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology / Q000502:physiology; D006801:Humans; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D014611:Vaccination; D019562:Viral Load
chemical_list: D018449:SAIDS Vaccines